Louisiana State Employees Retirement System Makes New Investment in Illumina, Inc. $ILMN

Louisiana State Employees Retirement System purchased a new stake in shares of Illumina, Inc. (NASDAQ:ILMN) during the 1st quarter, HoldingsChannel.com reports. The institutional investor purchased 44,300 shares of the life sciences company’s stock, valued at approximately $5,460,000.

Several other institutional investors and hedge funds have also modified their holdings of ILMN. Capital World Investors raised its holdings in shares of Illumina by 20.0% during the third quarter. Capital World Investors now owns 19,976,850 shares of the life sciences company’s stock worth $1,897,178,000 after acquiring an additional 3,331,542 shares in the last quarter. Invesco Ltd. grew its stake in Illumina by 97.0% in the fourth quarter. Invesco Ltd. now owns 2,747,986 shares of the life sciences company’s stock valued at $360,426,000 after purchasing an additional 1,352,731 shares in the last quarter. AQR Capital Management LLC increased its position in Illumina by 30.3% in the 4th quarter. AQR Capital Management LLC now owns 4,426,126 shares of the life sciences company’s stock worth $580,531,000 after purchasing an additional 1,028,099 shares during the last quarter. Morgan Stanley increased its position in Illumina by 66.0% in the 4th quarter. Morgan Stanley now owns 2,529,045 shares of the life sciences company’s stock worth $331,710,000 after purchasing an additional 1,005,474 shares during the last quarter. Finally, Nordea Investment Management AB raised its stake in shares of Illumina by 2,792.2% during the 4th quarter. Nordea Investment Management AB now owns 944,500 shares of the life sciences company’s stock worth $124,145,000 after purchasing an additional 911,843 shares in the last quarter. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Illumina Stock Performance

Shares of NASDAQ ILMN opened at $176.55 on Friday. The business’s 50-day simple moving average is $149.62 and its 200-day simple moving average is $137.66. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.36 and a current ratio of 1.75. Illumina, Inc. has a 52 week low of $88.00 and a 52 week high of $182.84. The firm has a market cap of $26.71 billion, a price-to-earnings ratio of 32.10, a P/E/G ratio of 3.32 and a beta of 1.50.

Illumina (NASDAQ:ILMN) last posted its earnings results on Thursday, April 30th. The life sciences company reported $1.15 earnings per share for the quarter, topping the consensus estimate of $1.05 by $0.10. The firm had revenue of $1.09 billion during the quarter, compared to analyst estimates of $1.07 billion. Illumina had a return on equity of 31.01% and a net margin of 19.42%.The company’s revenue for the quarter was up 4.8% on a year-over-year basis. During the same period in the previous year, the company earned $0.97 EPS. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. As a group, equities research analysts expect that Illumina, Inc. will post 5.21 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on ILMN shares. Evercore reiterated an “outperform” rating on shares of Illumina in a report on Friday, May 1st. Weiss Ratings raised shares of Illumina from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, June 3rd. Canaccord Genuity Group reduced their target price on shares of Illumina from $150.00 to $140.00 and set a “hold” rating for the company in a research note on Friday, May 1st. Citigroup boosted their target price on shares of Illumina from $80.00 to $95.00 and gave the stock a “sell” rating in a research report on Monday, May 4th. Finally, Barclays increased their price target on shares of Illumina from $122.00 to $145.00 and gave the stock an “underweight” rating in a research note on Wednesday. Eight equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, Illumina currently has a consensus rating of “Hold” and a consensus target price of $146.00.

Insider Activity

In related news, Director Keith A. Meister sold 235,000 shares of the company’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $163.63, for a total transaction of $38,453,050.00. Following the completion of the sale, the director directly owned 2,830,452 shares of the company’s stock, valued at approximately $463,146,860.76. This represents a 7.67% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Patricia Leckman sold 783 shares of the firm’s stock in a transaction on Friday, June 5th. The shares were sold at an average price of $162.59, for a total transaction of $127,307.97. Following the completion of the transaction, the senior vice president owned 21,259 shares in the company, valued at $3,456,500.81. The trade was a 3.55% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 1,003,769 shares of company stock valued at $155,710,908 over the last three months. Corporate insiders own 2.90% of the company’s stock.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.